GlassScriptPhysician profile
Tami Clinkenbeard
NPI 1033748736
$2,049.18
in general payments reported to CMS, 2019-2025
34 companies · $58.87 in 2025
The $58.87 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.69 · 2023: $41.29 · 2024: $1,931 · 2025: $58.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $191.81 | 2021-2024 | Keytruda, Welireg, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $187.23 | 2024 | Enhertu, Lynparza, Imfinzi |
| Stemline Therapeutics INC. | $183.91 | 2024 | Orserdu |
| Janssen Biotech, INC. | $174.54 | 2024 | Rybrevant, Darzalex |
| Glaxosmithkline, LLC. | $125.10 | 2024-2025 | Jemperli, Zejula, Shingrix |
| Regeneron Healthcare Solutions, INC. | $108.48 | 2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $93.70 | 2024 | |
| Eisai INC. | $91.87 | 2024 | |
| Lilly USA, LLC | $69.21 | 2023-2024 | Mounjaro, Verzenio, Retevmo |
| Exelixis INC. | $68.08 | 2024 | Cabometyx |
| Incyte Corporation | $60.29 | 2024 | Jakafi |
| Pfizer INC. | $55.90 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $54.99 | 2024 | Orgovyx |
| Abbvie INC. | $51.41 | 2024 | |
| Genentech USA, INC. | $46.45 | 2024 | Polivy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $41.84 | 2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $39.98 | 2024 | Opdivo |
| Coherus Oncology, INC. | $34.60 | 2024 | |
| Daiichi Sankyo INC. | $29.05 | 2024 | Enhertu |
| Jazz Pharmaceuticals INC. | $28.57 | 2024 | |
| Tempus Ai, INC | $28.01 | 2024 | |
| Nevro Corp. | $26.75 | 2024 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $24.85 | 2024 | Alunbrig |
| Agios Pharmaceuticals, INC. | $24.63 | 2024 | |
| Fennec Pharmaceuticals, INC. | $24.19 | 2024 | Pedmark |
| Adaptive Biotechnologies Corporation | $23.52 | 2024 | Clonoseq |
| Deciphera Pharmaceuticals INC. | $22.87 | 2024 | Qinlock |
| Iovance Biotherapeutics, INC. | $21.55 | 2024 | Amtagvi |
| Recordati_rare_diseases_inc. | $21.38 | 2024 | Sylvant |
| Servier Pharmaceuticals LLC | $20.34 | 2024 | |
| Genmab U.S., INC. | $20.28 | 2024 | Epkinly |
| Alnylam Pharmaceuticals INC. | $19.04 | 2024 | Givlaari |
| Immunocore Limited | $18.44 | 2024 | Kimmtrak |
| Puma Biotechnology, INC. | $16.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Clinkenbeard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.